Fig. 3From: Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: A prospective single center phase II studyDisease free survival of gemcitabine-mono (blue curve) and cisplatin-gemcitabine (green curve) patients. The median DFS of the patients receiving gemcitabine plus cisplatin was 28.8 months (95% CI not available), and 14.4 months (95% CI 9.5–19.3) in the patients receiving gemcitabine aloneBack to article page